We’re excited to share that applications are now open for the AI-driven Medicines (AIM) program.
The AI-driven Medicines (AIM) program aims to drive transformative research that leverages computational or digital-based methods and tools to address critical, real-world challenges in the discovery and development of accessible and affordable medicines. This initiative focuses on supporting the development of innovative methodologies and tools to accelerate the drug discovery and development pipeline, bridging the gap between advanced computational theory and practical therapeutic applications.
Projects that leverage computational or digital technologies (TRL 3-7), include a Canadian SME, and align with our open science principles can receive up to $1M CAD over one year to accelerate the development of accessible and affordable medicines.
The application process consists of two key phases: a Letter of Intent (LOI) application, followed by an invitation for selected applicants to submit a full proposal. We accept proposals on a rolling basis, applications will be evaluated individually, and grants will be awarded until no more funding is available.
If you’re working on or know of a project that could be a fit, we encourage you to apply or share this opportunity with your network.
